Lawson MA - Search Results

1

Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.

Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, Kaplan W, Paton-Hough J, Fellows C, Pettitt JA, Neil Dear T, Van Valckenborgh E, Baldock PA, Rogers MJ, Eaton CL, Vanderkerken K, Pettit AR, Quinn JM, Zannettino AC, Phan TG, Croucher PI. Lawson MA, et al. Nat Commun. 2015 Dec 3;6:8983. doi: 10.1038/ncomms9983. Nat Commun. 2015. PMID: 26632274 Free PMC article.

2

Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.

Vanderkerken K, Medicherla S, Coulton L, De Raeve H, Willems A, Lawson M, Van Camp B, Protter AA, Higgins LS, Menu E, Croucher PI. Vanderkerken K, et al. Cancer Res. 2007 May 15;67(10):4572-7. doi: 10.1158/0008-5472.CAN-06-4361. Epub 2007 May 10. Cancer Res. 2007. PMID: 17495322

3

Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.

Lawson MA, Coulton L, Ebetino FH, Vanderkerken K, Croucher PI. Lawson MA, et al. Biochem Biophys Res Commun. 2008 Dec 12;377(2):453-457. doi: 10.1016/j.bbrc.2008.09.157. Epub 2008 Oct 16. Biochem Biophys Res Commun. 2008. PMID: 18929536

4

Targeting RANK/RANKL in the treatment of solid tumours and myeloma.

Buckle CH, Neville-Webbe HL, Croucher PI, Lawson MA. Buckle CH, et al. Among authors: lawson ma. Curr Pharm Des. 2010;16(11):1272-83. doi: 10.2174/138161210791034021. Curr Pharm Des. 2010. PMID: 20166980 Review.

5

Bisphosphonate therapy in the treatment of multiple myeloma.

Lawson MA, Ashcroft J, Croucher PI. Lawson MA, et al. Curr Pharm Des. 2010;16(27):3028-36. doi: 10.2174/138161210793563608. Curr Pharm Des. 2010. PMID: 20722619 Review.

6

Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo.

Vitovski S, Chantry AD, Lawson MA, Croucher PI. Vitovski S, et al. Among authors: lawson ma. PLoS One. 2012;7(5):e35830. doi: 10.1371/journal.pone.0035830. Epub 2012 May 16. PLoS One. 2012. PMID: 22615740 Free PMC article.

7

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.

Buckle CH, De Leenheer E, Lawson MA, Yong K, Rabin N, Perry M, Vanderkerken K, Croucher PI. Buckle CH, et al. Among authors: lawson ma. PLoS One. 2012;7(8):e41127. doi: 10.1371/journal.pone.0041127. Epub 2012 Aug 29. PLoS One. 2012. PMID: 22952578 Free PMC article.

8

NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.

Lawson MA, Paton-Hough JM, Evans HR, Walker RE, Harris W, Ratnabalan D, Snowden JA, Chantry AD. Lawson MA, et al. PLoS One. 2015 Mar 13;10(3):e0119546. doi: 10.1371/journal.pone.0119546. eCollection 2015. PLoS One. 2015. PMID: 25768011 Free PMC article.

9

A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease.

Paton-Hough J, Chantry AD, Lawson MA. Paton-Hough J, et al. Among authors: lawson ma. Bone. 2015 Aug;77:57-68. doi: 10.1016/j.bone.2015.04.004. Epub 2015 Apr 11. Bone. 2015. PMID: 25868800 Review.

10

Mitotic quiescence, but not unique "stemness," marks the phenotype of bone metastasis-initiating cells in prostate cancer.

Wang N, Docherty F, Brown HK, Reeves K, Fowles A, Lawson M, Ottewell PD, Holen I, Croucher PI, Eaton CL. Wang N, et al. FASEB J. 2015 Aug;29(8):3141-50. doi: 10.1096/fj.14-266379. Epub 2015 Apr 17. FASEB J. 2015. PMID: 25888599 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

226 results

Search Page

Filters